These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19895944)

  • 1. High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome.
    Schwartz GG
    Am J Cardiol; 2009 Nov; 104(10 Suppl):46E-51E. PubMed ID: 19895944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
    Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG
    J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease.
    Vonbank A; Saely CH; Rein P; Drexel H
    Eur J Clin Invest; 2015 Oct; 45(10):1092-7. PubMed ID: 26255620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy and adverse cardiovascular events in patients with acute myocardial infarction.
    Ota T; Ishii H; Suzuki S; Tanaka A; Shibata Y; Tatami Y; Harata S; Shimbo Y; Takayama Y; Kawamura Y; Osugi N; Maeda K; Kondo T; Murohara T
    Am J Cardiol; 2015 Feb; 115(4):411-6. PubMed ID: 25555656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the efficacy of statin treatment in acute coronary syndromes.
    Rosa GM; Carbone F; Parodi A; Massimelli EA; Brunelli C; Mach F; Vuilleumier N; Montecucco F
    Eur J Clin Invest; 2014 May; 44(5):501-15. PubMed ID: 24601937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL cholesterol and residual risk of first cardiovascular events.
    Saely CH; Vonbank A; Drexel H
    Lancet; 2010 Nov; 376(9754):1738; author reply 1738-9. PubMed ID: 21093648
    [No Abstract]   [Full Text] [Related]  

  • 18. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
    Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.